Medicare's expanded coverage for donor-derived cell-free DNA testing removes a key reimbursement barrier, accelerating adoption of iMDx's GraftAssure assay in transplant diagnostics
Executive summary: Medicare issued a favorable coverage decision expanding reimbursement for donor-derived cell-free DNA testing in transplant care, specifically noting iMDx's GraftAssure assay portfolio. The decision eliminates a significant reimbursement hurdle, likely increasing assay adoption and driving revenue growth for iMDx in the transplant diagnostics market.
Who is involved: Insight Molecular Diagnostics Inc. (iMDx), the Centers for Medicare & Medicaid Services (CMS), transplant centers, and patients receiving transplant monitoring.
Likely next: Transplant programs are expected to adopt GraftAssure more widely, leading to higher assay volumes for iMDx and potential follow‑on coverage decisions by private payers.
On July 16, 2026, Medicare announced a favorable coverage decision that broadens reimbursement for donor-derived cell-free DNA (dd-cfDNA) testing used in transplant care. The move highlights iMDx's GraftAssure assay portfolio as a qualifying test under the new policy. By alleviating a major payment obstacle, the decision is expected to boost uptake of dd-cfDNA assays among transplant centers and support iMDx's commercial growth in this niche.
Timeline
- — Favorable Medicare Coverage Decision Supports Commercial Adoption of iMDx GraftAssure Assay Portfolio (GlobeNewswire)
Analysis — what this means
Sectors affected
- Donor-derived cell-free DNA testing
- Transplant diagnostics
- Molecular diagnostics
Regulatory implications
- Medicare's decision provides immediate reimbursement for dd-cfDNA transplant monitoring under existing CPT codes, effective July 16, 2026.